INTRODUCTION {#sec1-1}
============

Periodontal disease is the sequel to interplay between the host\'s defense mechanisms and plaque microorganisms. Cytokines are glycoprotein mediators that help immuno-inflammatory cells inter-communicate to affect an adequate immune response. Cytokine immunobiology pivots the development of numerous destructive inflammatory diseases such as autoimmune arthritis, Crohn\'s disease, and periodontitis.\[[@ref1]\]

The classical interleukin-1 (IL-1) cytokine clan especially is recognized to orchestrate disease processes and is identified as therapeutic targets. Excessive or abnormal activity of these agents, along with tissue destruction, is a hallmark of periodontitis.\[[@ref2][@ref3]\]

IL-33 is the newest entrant to the IL-1 family.\[[@ref4]\] IL-33 (IL-1F11 \[IL-1 Family member 11\]) is a bi-functional alarmin that not only links innate and adaptive immune responses as a cytokine but is also a nuclear factor.\[[@ref5][@ref6]\] It may function similar to the archetypal alarmin IL-1α, as an endogenic "red flag" to notify the innate immune system of tissue damage, as it can be released extracellularly following endothelial cell damage or mechanical injury.\[[@ref7]\] Reports from preceding studies delving into the part played by IL-33 in periodontal disease have been inconclusive.

Cytokines are the primary mediators of immunoregulation; therefore, the corresponding genetic regulatory factors concerned with cytokine function and periodontitis have been probed. Association between a composite genotype of the IL-1 gene with severe periodontitis has been found.\[[@ref8]\] Polymorphisms in the IL-33 gene have been found to be associated with Alzheimer\'s disease (AD) and rheumatoid arthritis.\[[@ref9][@ref10]\]

The aim of this investigation was to estimate IL-33 in gingival crevicular fluid (GCF) and plasma and to study the association of IL-33 gene single-nucleotide polymorphisms (SNPs) rs1157505 and rs7044343 in chronic periodontitis (CP) and generalized aggressive periodontitis (GAgP) patients.

MATERIALS AND METHODS {#sec1-2}
=====================

Study population {#sec2-1}
----------------

The current study comprised 90 subjects \[demographic data as in [Table 1](#T1){ref-type="table"}\] - thirty CP patients, 30 GAgP patients, and 30 healthy subjects, enlisted from the outpatient department of periodontics from June 2017 to April 2018. The purpose and procedure of the study were thoroughly explained to each participant before recruitment for the study, and informed consent was procured in writing. Approval for the same was given by the Institutional Ethical Committee and was executed according to the guidelines of the Helsinki Declaration of 1975, modified in 2013.

###### 

Descriptive statistics of the study population and gingival crevicular fluid and plasma interleukin-33 concentration

  Parameters                           Group H (*n*=30)   Group CP (*n*=30)   Group GAgP (*n*=30)   *F*^†^/*χ*^2^   *P*
  ------------------------------------ ------------------ ------------------- --------------------- --------------- -----------
  Age (years)                          26.30±5.421        39.87±9.486         27.43±6.709           31.018          \<0.001\*
  Sex                                                                                                               
   Females (*n*)                       14                 14                  11                    4.727           0.094
   Males (*n*)                         16                 16                  19                                    
  GI                                   NA                 1.92±0.317          2.40±0.255            42.146          \<0.001\*
  PPD (mm)                             1.93±0.740         6.30±1.264          6.63±1.189            174.066         \<0.001\*
  PAL (mm)                             NA                 7.33±1.626          7.57±1.165            0.408           0.525
  GCF IL-33 concentration (pg/ml)      417.13±43.244      469.27±50.803       556.65±82.737         51.262          \<0.001\*
  Plasma IL-33 concentration (pg/ml)   13.86±4.452        16.41±8.225         204.32±147.938        58.961          \<0.001\*

\*Statistically significant at *P*\<0.05; ^†^*F* -- Kruskal--Wallis test. All values except sex have been expressed as mean±SD. SD -- Standard deviation; NA -- Not applicable; H -- Healthy; CP -- Chronic periodontitis; GAgP -- Generalized aggressive periodontitis; *n* -- Number of subjects; mm -- Millimeter; pg/ml -- Picogram per milliliter; GI -- Gingival index; PPD -- Probing pocket depth; PAL -- Probing attachment level; GCF -- Gingival crevicular fluid; IL -- Interleukin; *P* -- Probability; *χ*^2^ -- Chi-square

Comprehensive systemic as well as dental histories of every participant were recorded. Nonsmoking dentulous subjects with a minimum of 20 teeth were selected for this study. Subjects with a significant medical history such as diabetes mellitus or autoimmune diseases; who had received any form of periodontal treatment or antibiotics or other medication in the previous half year; pregnant and lactating females formed the exclusion criteria for this study. Patients were selected as per the proposed criteria of the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.\[[@ref11]\]

Periodontal evaluation included gingival index (GI),\[[@ref12]\] probing pocket depth (PPD), probing attachment level (PAL), and presence or absence of sulcular bleeding upon probing. PPD and PAL were measured using William\'s periodontal probe (William\'s periodontal probe, Hu-Friedy, Illinois, USA). Orthopantomographic examination was carried out. On the basis of the evaluation done by a single investigator, the study population selected was sorted into the aforementioned study groups.

The subjects with generalized chronic and aggressive periodontitis were selected based on the primary features and clinical presentation as defined by Lang *et al.*\[[@ref13]\]

Sample site selection for gingival crevicular fluid collection {#sec2-2}
--------------------------------------------------------------

Different sites (two to four sites/subject) were sampled to obtain a suitable volume of GCF in healthy subjects.\[[@ref14]\] In the CP and GAgP groups, a single sampling site with the greatest PAL along with radiographic evidence of alveolar bone resorption was chosen per subject.

At the subsequent appointment, GCF was collected with Periopaper strips (Periopaper, Ora Flow Inc., Smith-town, USA) by the atraumatic method described by Garg *et al.*\[[@ref14]\] Blood- and saliva-contaminated samples were disposed of. The sample GCF volume in the Periopaper strip was quantified by Periotron 8000 (Periotron 8000, Ora Flow Inc., Smith-town, USA) and transferred to microcentrifuge tubes (with identification markings) containing 0.4 mL of phosphate-buffered saline and stored at −80°C till the assay was run.

DNA and plasma extraction {#sec2-3}
-------------------------

Ten milliliters of blood was obtained from each participant by venipuncture. Two milliliters of the blood was used for plasma separation. The plasma was stored in a plastic vial at −80°C until the time of assay. The remaining 8 ml of the whole blood sample was promptly transported in ethylenediaminetetraacetic acid-coated vacutainers in the molecular genetics laboratory for DNA extraction and subsequent SNP analysis of IL33 gene.

Interleukin-33 analysis by enzyme-linked immunosorbent assay {#sec2-4}
------------------------------------------------------------

IL-33 concentration in GCF and plasma, obtained from the study subjects, were measured using Human IL-33 DuoSet ELISA kit (R and D Systems, USA, Imported by Biotech-India, India) and estimated using the standard curve, in accordance with the instructions provided in the kit insert.

Interleukin-33 gene single-nucleotide polymorphism genotyping by polymerase chain reaction {#sec2-5}
------------------------------------------------------------------------------------------

### DNA analysis {#sec3-1}

Miller\'s method\[[@ref15]\] was used to extract DNA after processing the blood sample. The DNA was quantified using a NanoDrop spectrophotometer (NanoDrop 1000 Spectrophotometer, Thermo Fisher Scientific, Wilmington, DE, USA), and the quantified DNA was analyzed on 0.8% agarose gel and 150--200 ng of DNA was used for the polymerase chain reaction (PCR) reaction.

### Primer designing and polymerase chain reaction-restriction fragment length polymorphism {#sec3-2}

The SNPs analyzed were rs1157505 (C/G) and rs7044343(C/T), both of which are intronic variants. Genotyping was carried out by PCR-restriction fragment length polymorphism as described by Chapuis *et al.*\[[@ref9]\] The PCR products were analyzed by electrophoresis and visualized under ultraviolet illumination (Box, Syngene, Frederick, MD, USA).

Statistical analyses {#sec2-6}
--------------------

Statistical Package for the Social Science (SPSS^®^ version 18.5, SPSS Inc., Chicago, USA) software was applied for statistical analyses. The distribution of data was assessed for normality using Shapiro--Wilk test. Chi-square test was employed to analyze the descriptive data, allelic frequencies of IL33 SNPs, and its deviation from the Hardy--Weinberg equilibrium\[[@ref16]\] in the study population. The intergroup genotypes and clinical parameters in relation to IL-33 concentration in GCF and plasma were analyzed by Kruskal--Wallis test and Mann--Whitney U-test. Correlation between clinical and biochemical parameters was evaluated using the Spearman rank test.

RESULTS {#sec1-3}
=======

Clinical and biochemical findings {#sec2-7}
---------------------------------

Descriptive statistics of the three groups are tabulated as seen in [Table 1](#T1){ref-type="table"}. IL-33 was detected in all the samples. The GAgP group had the highest mean IL-33 concentration in GCF and plasma. The GCF concentration of IL-33 differed significantly between the three groups. The plasma concentration of IL-33 differed significantly between groups H and GAgP (*P* \< 0.001) and the groups CP and GAgP (*P* \< 0.001). GCF and plasma concentration of IL-33 was found to be statistically independent of GI, PPD, or PAL in any group.

Genotype frequencies {#sec2-8}
--------------------

The observed genotype distribution for both the SNPs was in accordance with the Hardy--Weinberg equilibrium. The distribution of genotypes in subjects of the three groups is given in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. The frequency of IL33 SNP rs1157505 GG allele was greatest in GAgP (26.7%) compared to other groups. IL33 SNP rs7044343 TC genotype correlated with the lowest PPD in the healthy group (*P* = 0.030). The GG genotype subjects had the highest levels of IL-33 in GCF and plasma. IL33 rs7044343 TT genotype subjects of the healthy group had the highest plasma concentration of IL-33 \[Tables [2](#T2){ref-type="table"}--[5](#T5){ref-type="table"}\]. The CC and CG variants of rs1157505 SNP, when divided into individual groups, varied significantly in the levels of GCF and plasma IL-33, whereas the GG variant did not show a statistically significant inter-group difference in IL-33 concentration in GCF and plasma. The CC, TC, and TT variants of rs7044343 SNP, when divided into individual groups, showed a statistically significant difference in the levels of GCF IL-33 and plasma IL-33 between the groups.

![Distribution of interleukin-33 allelic variants of single-nucleotide polymorphism rs1157505 in the study population](JISP-23-424-g001){#F1}

![Distribution of interleukin-33 allelic variants of single-nucleotide polymorphism rs7044343 in the study population](JISP-23-424-g002){#F2}

###### 

Correlation of genotype rs1157505 (C/C, C/G, G/G) with respect to gingival crevicular fluid and plasma interleukin-33

  Group        rs1157505   *n*              GCF IL-33 concentration (pg/ml), mean±SD   *χ*^2^\*   *P*     Plasma IL-33 concentration (pg/ml), mean±SD   *χ*^2^\*   *P*
  ------------ ----------- ---------------- ------------------------------------------ ---------- ------- --------------------------------------------- ---------- -------
  Group H      CC          13               410.32±43.93                               0.954      0.621   14.57±3.242                                   3.045      0.218
  CG           16          423.88±44.248    13.57±5.285                                                                                                            
  GG           1           397.8            9.19                                                                                                                   
  Group CP     CC          19               471.89±56.851                              0.275      0.872   17.26±9.48                                    1.431      0.489
  CG           10          462.64±41.934    15.39±5.616                                                                                                            
  GG           1           485.8            10.39                                                                                                                  
  Group GAgP   CC          7                523.01±57.688                              2.247      0.325   199.36±185.592                                1.509      0.47
  CG           15          559.12±72.785    175.28±131.091                                                                                                         
  GG           8           581.46±114.299   263.13±144.885                                                                                                         

\*Kruskal--Wallis test, *P*\<0.05 considered as statistically significant. - NA -- Not applicable; IL -- Interleukin; *n* -- Number of subjects; pg/ml -- Picogram per milliliter; GCF -- Gingival crevicular fluid; SD -- Standard deviation; H -- Healthy; CP -- Chronic periodontitis; GAgP -- Generalized aggressive periodontitis; CC -- Homozygous dominant genotype; CG -- Heterozygous genotype; GG -- Homozygous recessive genotype; *P* -- Probability; *χ*^2^ -- Chi-square

###### 

Correlation of genotype rs7044343 (C/C, T/C, T/T) with respect to gingival crevicular fluid and plasma interleukin-33

  Group        rs7044343   *n*              GCF IL-33 concentration (pg/ml), mean±SD   *χ*^2^\*   *P*     Plasma IL-33 concentration (pg/ml), mean±SD   *χ*^2^\*   *P*
  ------------ ----------- ---------------- ------------------------------------------ ---------- ------- --------------------------------------------- ---------- ----------
  Group H      CC          3                431.57±42.725                              1.018      0.601   11.52±2.183                                   8.953      0.011^†^
  TC           18          416.24±31.347    12.37±3.695                                                                                                            
  TT           9           414.11±64.377    17.61±4.336                                                                                                            
  Group CP     CC          2                463.43±31.643                              0.949      0.622   9.72±0.936                                    4.064      0.131
  TC           19          462.42±49.749    15.91±7.881                                                                                                            
  TT           9           485.03±57.118    18.95±9.293                                                                                                            
  Group GAgP   CC          9                563.38±119.275                             0.07       0.966   214.36±139.742                                0.302      0.86
  TC           14          542.63±37.042    210.62±155.36                                                                                                          
  TT           7           576.06±100.887   178.83±162.622                                                                                                         

\*Kruskal--Wallis test, ^†^Statistically significant at *P*\<0.05. IL -- Interleukin; *n* -- Number of subjects; pg/ml -- Picogram per milliliter; GCF -- Gingival crevicular fluid; SD -- Standard deviation; H -- Healthy; CP -- Chronic periodontitis; GAgP -- Generalized aggressive periodontitis; CC -- Homozygous dominant genotype; TC -- Heterozygous genotype; TT -- Homozygous recessive genotype; *P* -- Probability; *χ*^2^ -- Chi-square

###### 

Correlation of genotype rs1157505 (C/C, C/G, G/G) with respect to gingival crevicular fluid and plasma interleukin-33 levels irrespective of groups

  Allele   *n*   GCF IL-33 levels (pg/ml), mean±SD   *χ*^2^           *P\**\*    Plasma IL-33 levels (pg/ml), mean±SD   *χ*^2^   *P\**
  -------- ----- ----------------------------------- ---------------- ---------- -------------------------------------- -------- ----------
  CC       39    460.54±65.666                       7.631            0.022^†^   49.05±102.754                          7.572    0.023^†^
  CG       41    482.81±81.603                       73.18±110.442                                                               
  GG       10    553.53±118.569                      212.46±166.544                                                              

\**P* values of Chi-square test, ^†^Statistically significant at *P*\<0.05. *n* -- Number of subjects; GCF -- Gingival crevicular fluid; IL -- Interleukin, pg/ml -- Picogram per milliliter; SD -- Standard deviation; CC -- Homozygous dominant genotype; CG -- Heterozygous genotype; GG -- Homozygous recessive genotype; *P* -- Probability; *χ*^2^ -- Chi-square

###### 

Correlation of genotype rs7044343 (C/C, T/C, T/T) with respect to gingival crevicular fluid and plasma interleukin -33 levels irrespective of groups

  Allele   *n*   GCF IL-33 levels (pg/ml), mean±SD   *χ*^2^          *P*\*   Plasma IL-33 levels (pg/ml), mean±SD   *χ*^2^   *P*\*
  -------- ----- ----------------------------------- --------------- ------- -------------------------------------- -------- -------
  CC       14    520.85±112.746                      2.574           0.276   141.66±149.209                         3.376    0.155
  TC       51    468.14±64.167                       68.11±118.923                                                           
  TT       25    484.99±96.524                       63.23±109.818                                                           

\**P* values of Chi-square test, *P*\<0.05 considered statistically significant. *n* -- Number of subjects; GCF -- Gingival crevicular fluid; IL -- Interleukin; pg/ml -- Picogram per milliliter; SD -- Standard deviation; CC -- Homozygous dominant genotype; TC -- Heterozygous genotype; TT -- Homozygous recessive genotype; *P* -- Probability; *χ*^2^ -- Chi-square

DISCUSSION {#sec1-4}
==========

In the current cross-sectional research, IL-33 levels in the GCF and plasma were correlated with its SNPs rs1157505 and rs7044343. It is well documented that there is an increase and activation of several cytokines during the progression of periodontal disease.\[[@ref17][@ref18]\] Since the IL-1 family of cytokines is affective in degenerative disorders such as periodontitis and rheumatoid arthritis,\[[@ref1]\] our study aimed to quantify the concentration of IL-33 in GCF and plasma in periodontal disease.

The results of previous studies, by various researchers who have quantified IL-33 in periodontal disease, have been quite contradictory. While *in vitro* studies prove the central role of IL-33 in periodontitis,\[[@ref19][@ref20][@ref21][@ref22]\] most human studies have reported the contrary.\[[@ref23][@ref24][@ref25][@ref26]\] Initial studies reporting the absence of IL-33 in GCF attributed it to less sensitive ELISA kits and ethnic variation in their study population.\[[@ref24]\] In the current study, IL-33 was detected in GCF and plasma, which may be due to a newer, more sensitive ELISA kit. Studies that detected IL-33 in GCF, saliva, and plasma have reported that IL-33 levels cannot discern chronic periodontitis patients from healthy individuals.\[[@ref25]\]

IL-33 not only functions as an alarmin but also functions as a systemic chemokine.\[[@ref27]\] The higher concentration of IL-33 in GCF compared to plasma in our study may be the result of increase in local production of IL-33 from the increased vasculature in diseased periodontal tissues or from periodontal tissue destruction.\[[@ref4][@ref27][@ref28][@ref29]\] Since we have included systemically healthy subjects, the higher IL-33 plasma concentration in periodontitis groups might be due to a spill-over from the periodontal tissues into the systemic circulation.

In our study, PPD and PAL measurements were greater in CP and GAgP groups as anticipated. The IL-33 concentration did not correlate with clinical parameters of inflammation. The quiescent or active state of the episodic periodontitis may not be portrayed accurately by PPD, PAL, and GI. Moreover, they are all soft tissue measurements and do not reflect active bone resorption. Analyses of GCF components give an accurate indication of the link between specific metabolic variation and disease status.\[[@ref23]\] Hence, the concentration of IL-33 might be a true indicator of the periodontal disease activity in the absence of evident changes in the soft tissue parameters.

In initial stages of inflammation, IL-33 augments the Th2 response, which is anti-inflammatory.\[[@ref27]\] However, due to high levels of proinflammatory cytokines in periodontal disease in response to the bacterial infection, IL-33 production is stimulated and osteoclastogenesis may be favored.\[[@ref30][@ref31]\] In addition, mast cell degranulation stimulates the differentiation of circulating CD14(+) monocytes into osteoclasts.\[[@ref30][@ref32][@ref33][@ref34]\] This could explain the commensurate increase in concentration of IL-33 in periodontitis compared to healthy subjects.

Mendonça *et al.* have reported increased IL-33 levels in the saliva of systemic lupus erythematosus patients with chronic periodontitis.\[[@ref35]\] Gümüş *et al.* found that salivary levels of IL-33 are higher in chronic periodontitis groups.\[[@ref36]\] Nizam *et al.* have quantified and noted increased salivary cytokines, including IL-33 in sleep apnea patients as compared to controls.\[[@ref37]\] In recent implant studies, IL-33 levels in peri-implantar crevicular fluid were seen to be significantly higher in peri-implantitis and peri-implant mucositis group when compared to healthy group.\[[@ref38]\] Peri-implant fluid levels of IL-33 from mucositis sites were seen to be independent of the degree of bone resorption around implants or teeth.\[[@ref39]\]

IL33 SNPs rs7044343 and rs11792633 have been studied in various diseases such as Behçet\'s disease,\[[@ref40][@ref41]\] systemic sclerosis, and rheumatoid arthritis,\[[@ref10][@ref42]\] whereas rs1157505 is associated with the risk of developing AD.\[[@ref9][@ref43]\] There have been no studies which probe into the association of IL-33 gene polymorphism with periodontal disease, in hitherto published literature.

We found a significant difference between the distribution of the rare allelic variant (G/G) of rs1157505 SNP between the three study groups. It was seen that the rare allele variant GG genotype was associated with the highest concentrations of IL-33 in GCF and plasma and GAgP patients exhibited the highest concentrations of IL-33, irrespective of the genotype. The results of the genetic correlation are to be interpreted cautiously, until such a time that follow up studies, with larger sample sizes, of currently healthy subjects with the GG genotype can be done to ascertain if the G allele is indeed a risk allele for periodontal disease.

IL-33 appears to be a promising biomarker for periodontal health and disease and future interventional studies may help comprehend its exact role in periodontitis opening new avenues for periodontal therapy. IL33 SNPs have to be studied more closely to investigate the genetic milieu of disease progression and to assess the reciprocal influence of other closely related genes. Future multicenter genetic studies with larger sample sizes studying the potential effect of IL-33 and its gene polymorphism in periodontitis associated with AD and diabetes mellitus are required for a more complete understanding.
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